[go: up one dir, main page]

WO2003018609A3 - Application de conjugues peptides a la maladie d'alzheimer - Google Patents

Application de conjugues peptides a la maladie d'alzheimer Download PDF

Info

Publication number
WO2003018609A3
WO2003018609A3 PCT/US2002/026889 US0226889W WO03018609A3 WO 2003018609 A3 WO2003018609 A3 WO 2003018609A3 US 0226889 W US0226889 W US 0226889W WO 03018609 A3 WO03018609 A3 WO 03018609A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
application
peptide conjugates
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/026889
Other languages
English (en)
Other versions
WO2003018609A2 (fr
Inventor
Stanley Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002327514A priority Critical patent/AU2002327514A1/en
Publication of WO2003018609A2 publication Critical patent/WO2003018609A2/fr
Publication of WO2003018609A3 publication Critical patent/WO2003018609A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé chimique et son procédé d'utilisation dans le diagnostic et le traitement de la maladie d'Alzheimer. Au moins la séquence des isomères-D des acides aminés (phénylalanine-phénylalanine-valine-leucine-lysine) est en mesure de traverser la barrière sang-cerveau, de reconnaître la formation de plaques, caractéristique de la pathogénie de la maladie d'Alzheimer, et de perturber la formation d'une fibrille du peptide amyloïde beta par inhibition du processus de la maladie.
PCT/US2002/026889 2001-08-23 2002-08-23 Application de conjugues peptides a la maladie d'alzheimer Ceased WO2003018609A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002327514A AU2002327514A1 (en) 2001-08-23 2002-08-23 Application of peptide conjugates to alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31438201P 2001-08-23 2001-08-23
US60/314,382 2001-08-23

Publications (2)

Publication Number Publication Date
WO2003018609A2 WO2003018609A2 (fr) 2003-03-06
WO2003018609A3 true WO2003018609A3 (fr) 2003-10-16

Family

ID=23219731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026889 Ceased WO2003018609A2 (fr) 2001-08-23 2002-08-23 Application de conjugues peptides a la maladie d'alzheimer

Country Status (2)

Country Link
AU (1) AU2002327514A1 (fr)
WO (1) WO2003018609A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608960D0 (en) * 2006-05-05 2006-06-14 St Georges Hosp Medical School Imaging agent
WO2008050133A2 (fr) * 2006-10-27 2008-05-02 Zapaloid Limited Inhibition d'une agrégation de beta-amyloïde
GB0716885D0 (en) * 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
US9579358B2 (en) 2011-10-10 2017-02-28 Lancaster University Business Enterprises Limited Compositions for binding to amyloid proteins
CN113061161B (zh) * 2021-04-02 2023-09-12 河南省农业科学院动物免疫学重点实验室 靶向amyloid-beta结构的抑制性肽配基及应用
CN114933635B (zh) * 2021-08-29 2023-05-19 武汉夫图生物科技有限公司 纳米小肽fh及其在制备治疗及预防眼底血管疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Also Published As

Publication number Publication date
AU2002327514A1 (en) 2003-03-10
WO2003018609A2 (fr) 2003-03-06

Similar Documents

Publication Publication Date Title
WO2002094191A3 (fr) Detection des amyloides de la maladie d'alzheimer au moyen de l'imagerie par resonance magnetique (irm)
EP2082747A3 (fr) Traitement de la maladie d' Alzheimer
FR2824568B1 (fr) Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2002223640A1 (en) Fusion proteins as immunization treatments of alzheimer's disease
GEP20043407B (en) Method of Inhibiting Amyloid Protein Aggregation and Imaging Amyloid Deposits Using Isoindoline Derivatives
WO2003039454A8 (fr) Inhibiteurs de la beta-secretase et leurs procede d'utilisation
WO2004074232A8 (fr) Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
WO1995018616A3 (fr) 8-aza, 6-aza et 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones et leur utilisation comme antagonistes du recepteur de la glycine ou du nmda
AU2002363825A1 (en) Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
WO2000076489A3 (fr) Procede d'inhibition de l'agregation de proteines amyloides et de formation d'images de depots amyloides
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003018609A3 (fr) Application de conjugues peptides a la maladie d'alzheimer
WO2002035987A3 (fr) Methodes d'identification de traitements de la neurotoxicite dans la maladie d'alzheimer engendree par des peptides $g(b)-amyloides
WO2003068147A3 (fr) Traitements de la neurotoxicite dans la maladie d'alzheimer
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
EP1181550A4 (fr) Procedes d'identification de composes pour le traitement de la maladie d'alzheimer
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
AU2002303957A1 (en) Method of treating alzheimer's disease with se-containing peptide
FR2800066B1 (fr) Procede de preparation de cetones par pyrogenation d'aldehydes, d'alcools, d'acides ou d'esters
WO2001090139A3 (fr) Ligand pour ameliorer l'administration d'agents biologiques par voie orale et via le systeme nerveux central
WO2001093896A3 (fr) Procede de traitement de la maladie d'alzheimer au moyen d'une proteine pouvant etre extraite d'organes de mammiferes
WO2004074313A3 (fr) Procedes et prediction de formation de fibrilles amyloides et d'identification de peptides utiles en tant qu'agents therapeutiques et diagnostiques
RU2001108801A (ru) Способ профилактики и лечения желчекаменной болезни
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP